Glycyrrhizin
Phase 2Small molecule
Glycyrrhizin is one of 38 small molecule programs targeting Prostate Cancer. It is currently in Phase 2.
2
Indications
3
Total Trials
2
Active Trials
37
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
312 competitors in Prostate Cancer
#DrugCompanyPhaseTrials
1Opdivo
Bristol-Myers SquibbPhase 3
Lupron
EEastern Cooperative Oncology Group
Phase 3
Nizoral
WWim Janssens
Phase 3
Fluciclovine
UUniversity of Utah
Phase 3
Gallium Ga 68 Gozetotide
MMayo Clinic
Phase 3
Rhpsma-7.3 (18f)
BBlue Earth Diagnostics
Phase 3
Trexall
Jazz PharmaceuticalsPreclinical
Jatenzo
GGrupo Espanol de Tumores Neuroendocrinos
Preclinical
Glycyrrhizin
MMansoura University
Phase 2
Botox
VVitae Pharmaceuticals Inc., an Allergan affiliate
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Randomized Controlled Trial1 trial
Medication1 trial
Revascularization of Young Immature Permenant Teeth Using Different Types of Intra Canal Medication
Not yet recruiting·—·N/A·NCT07236567·45 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Glycyrrhizin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- MMansoura University